Schulze G E, Boysen B G
Hazleton Washington, Inc., Department of Toxicology, Vienna, Virginia 22182.
Fundam Appl Toxicol. 1991 Apr;16(3):602-15. doi: 10.1016/0272-0590(91)90099-p.
The effects of two known neurotoxicants, acrylamide (ACR) and 3',3'-iminodipropionitrile (IDPN), were assessed using a functional observational battery (FOB), a measurement of motor activity (MA), and neuropathology (NP) in the context of a safety evaluation study. One hundred Sprague-Dawley rats (10/sex/group) were tested initially and then doses with vehicle, ACR (10 or 30 mg/kg/day), or IDPN (50 or 125 mg/kg/day) by oral gavage 7 days/week for 5 weeks (except where otherwise indicated). Neurobehavioral assessments were conducted prior to initiating treatment at 1, 6, and 24 hr after the first dose, and weekly thereafter. Body weight and food consumption were determined weekly, and animals were observed twice daily for signs of toxicity. Blood samples were obtained at termination for routine clinical pathology studies. At termination three animals/sex/group were perfused in situ for neuropathology evaluations and the remaining animals were necropsied for standard histological evaluations. Prominent neurological signs were observed in high-dose animals after 2 weeks, and significant mortality occurred in high-dose ACR animals during Week 3. A 7- or 10-day recovery period was initiated after 20 or 22 daily doses for high-dose IDPN and ACR animals, respectively. ACR and IDPN affected body weight, body-weight gain, food consumption, general activity (horizontal and vertical), urination, muscle tone (grip strength), motor reflexes, gait, and posture. Significant sex effects were seen in animals exposed to IDPN, with males being more severely affected. Microscopic examination of nervous system tissue and selected organs revealed minimal to moderately severe axonal swelling characterized by the presence of enlarged balloon-like axons in the brainstem and the cervical and lumbar cord of IDPN-treated animals. This change was most prominent in males and most severe in the lumbar spinal cord. An increased incidence of chronic progressive nephropathy was also noted in IDPN-treated rats. ACR-treated animals exhibited minimal to moderate degeneration in the cervical and lumbar spinal cord, the gasserian and dorsal root ganglia, and the tibial, sciatic, and sural nerves which were characterized by changes in axonal diameter, increased argyrophilia of axons, and disruption, fragmentation, and distortion of axons and the myelin sheath. Granulomatous inflammation in the lungs of high-dose ACR animals resulted from inhalation of feed, most probably due to partial paralysis or incoordination during feeding.
在一项安全性评估研究中,使用功能观察组合(FOB)、运动活性测量(MA)和神经病理学(NP)方法,评估了两种已知神经毒素丙烯酰胺(ACR)和3',3'-亚氨基二丙腈(IDPN)的影响。最初对100只Sprague-Dawley大鼠(每组10只/性别)进行测试,然后通过每周7天经口灌胃给予赋形剂、ACR(10或30 mg/kg/天)或IDPN(50或125 mg/kg/天),持续5周(另有说明的除外)。在开始治疗前、首次给药后1、6和24小时以及此后每周进行神经行为评估。每周测定体重和食物消耗量,每天观察动物两次以检查毒性迹象。在处死时采集血样用于常规临床病理学研究。处死时,每组/性别取3只动物进行原位灌注以进行神经病理学评估,其余动物进行尸检以进行标准组织学评估。高剂量组动物在2周后出现明显的神经体征,高剂量ACR组动物在第3周出现显著死亡。高剂量IDPN和ACR组动物分别在每日给药20或22次后开始7天或10天的恢复期。ACR和IDPN影响体重、体重增加、食物消耗量、一般活动(水平和垂直方向)、排尿、肌张力(握力)、运动反射、步态和姿势。在接触IDPN的动物中观察到显著的性别效应,雄性受影响更严重。对神经系统组织和选定器官的显微镜检查显示,IDPN处理的动物脑干、颈髓和腰髓中存在轻度至中度严重的轴突肿胀,表现为轴突呈气球样增大。这种变化在雄性中最为明显,在腰髓中最为严重。在IDPN处理的大鼠中还发现慢性进行性肾病的发病率增加。ACR处理的动物在颈髓和腰髓、三叉神经节和背根神经节以及胫神经、坐骨神经和腓肠神经中表现出轻度至中度的变性,其特征为轴突直径改变、轴突嗜银性增加以及轴突和髓鞘的破坏、断裂和扭曲。高剂量ACR组动物肺部的肉芽肿性炎症是由于吸入饲料引起的,很可能是由于喂食期间部分麻痹或不协调所致。